Shiga toxin-producing Escherichia coli infection

Clinical Infectious Diseases

Volumn 38, Issue 9, 2004, Pages 1298-1303

  Thorpe, Cheleste M ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; FOSFOMYCIN; NEUTRALIZING ANTIBODY; QUINOLONE; SHIGA TOXIN; TRIMETHOPRIM; ESCHERICHIA COLI VACCINE;

ABDOMINAL PAIN; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FECES ANALYSIS; GASTROINTESTINAL TRACT; HEMOLYTIC UREMIC SYNDROME; HOST CELL; HUMAN; HYDRATION; IMMUNIZATION; KIDNEY FAILURE; LATEX AGGLUTINATION TEST; META ANALYSIS; NAUSEA AND VOMITING; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; AGED; ANIMAL; CHEMISTRY; CHILD; ENTEROBACTER INFECTION; EPIDEMIC; KIDNEY DISEASE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

AGED; ANIMALS; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY DISEASES; MIDDLE AGED; SHIGA TOXIN;

EID: 2342618145     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383473     Document Type: Article

References (27)

1. Konowalchuk J, Speirs JI, Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun 1977; 18:775-9.
2. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of hemolytic-uremic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 2:619-20.
3. Siegler RL. Postdiarrheal Shiga toxin-mediated hemolytic uremic syndrome. JAMA 2003; 290:1379-81.
4. Griffin PM. Epidemiology of 283 outbreaks of Escherichia coli O157: H7 infections in the 20th Century, United States [abstract O-2]. In: Program and abstracts of the 5th International Symposium on Shiga Toxin (Verocytotoxin)- Producing Escherichia coli Infections (Edinburgh, Scotland). VTEC 2003 Organizing Committees, 2003:17.
5. OBrien SJ, Adak GI. Escherichia coli O157:H7: piecing together the jigsaw puzzle. N Engl J Med 2002; 347:608-9.
6. Jelacic JK, Damrow T, Chen GS, et al. Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and clinical profiles. J Infect Dis 2003; 188:719-29.
7. Andreoli SP, Trachtman H, Acheson DWK, et al. Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr Nephrol 2002; 17:293-8.
8. Banatvala N, Griffin PM, Greene KD, et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiological, serological, clinical and epidemiological findings. J Infect Dis 2001; 183:1063-70.
9. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998; 11:450-79.
10. Thorpe CM, Ritchie JM, Acheson DWK. Enterohemorrhagic and other Shiga toxin-producing E. coli. In M. Donnenberg, ed. E. coli: virulence mechanisms of a versatile pathogen. New York: Academic Press, 2002: 119-41.
11. Slutsker L, Ries AA, Greene KD, et al. Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med 1997; 126:505-13.
12. Hurley BP, Thorpe CM, Acheson DWK. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001; 69:6140-7.
13. Siegler RL, Pysher TJ, Lou R, et al. Response to Shiga toxin 1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome. Am J Nephrol 2001; 21:420-5.
14. Matussek A, Lauber J, Bergau A, et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood 2003; 102:1323-32.
15. Ochoa TJ, Cleary TG. Epidemiology and spectrum of disease of Escherichia coli O157. Curr Opin Infect Dis 2003; 16:259-63.
16. Guerrant RL, van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331-51.
17. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 2002; 288:996-1001.
18. Wagner PL, Neely MN, Zhang X, et al. Role for a phage promoter in Shiga toxin 2 expression from a pathogenic Escherichia coli strain. J Bacteriol 2001; 183:2081-5.
19. Zhang X, McDaniel AD, Wolf LE, et al. Quinolone antibiotic induces Shiga toxin-encoding bacteriophages, toxin production and death in mice. J Infect Dis 2000; 181:664-70.
20. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930-6.
21. Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346:23-32.
22. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003; 290:1360-70.
23. Siegler RL. The hemolytic uremic syndrome. Pediatr Clin North Am 1995; 42:1505-29.
24. Gagnadoux MF, Habib R, Gubler MC. Long term (15-25 years) outcome of childhood hemolytic uremic syndrome. Clin Nephrol 1996; 46:39-41.
25. Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003; 290:1337-44.
26. Potter AA, Klashinsky S, Li Y, et al. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 2004; 22:362-9.
27. Centers for Disease Control and Prevention. Multistate outbreak of Escherichia coli O157:H7 infections associated with eating ground beef. MMWR Morb Mortal Wkly Rep 2002; 51:637.